![]() |
市場調查報告書
商品編碼
1492689
可待因市場:按配方、等級、應用、分銷管道和最終用戶分類 - 2024-2030 年全球預測Codeine Market by Formulation (Capsule, Syrup, Tablet), Grade (Laboratory Grade, Pharmaceutical Grade), Application, Distribution Channel, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年可待因市場規模為39.3億美元,預計2024年將達41.1億美元,2030年將達到54億美元,複合年成長率為4.65%。
可待因是一種鴉片類藥物和氫可酮的前驅藥物。它被添加到各種藥物中,例如錠劑和糖漿,或與其他藥物組合使用。與慢性疼痛相關的慢性疾病的增加增加了對可待因等有效鎮痛藥物的需求。老年人口的增加和醫療基礎設施的持續擴張正在推動市場成長,特別是在新興經濟體。然而,由於可待因可能被濫用,且持續的全球鴉片危機導致含可待因的鴉片類藥物處方量減少,嚴格的監管阻礙了市場擴張。不斷增加的研發活動旨在開發可維持治療功效的防濫用製劑,預計將為市場成長創造機會。人們擴大尋求新型藥物輸送系統,例如針對個人遺傳特徵的緩釋性膠囊和精準醫療方法,正在擴大市場基礎。
主要市場統計 | |
---|---|
基準年[2023] | 39.3億美元 |
預測年份 [2024] | 41.1億美元 |
預測年份 [2030] | 54億美元 |
複合年成長率(%) | 4.65% |
區域洞察
美國和加拿大擁有強大的製藥業,促進可待因治療藥物的生產和分銷。此外,研究和開發工作正在進行中,以創新含有可待因的疼痛管理療法,預計這將成為美洲市場成長的基礎。南美國家,特別是巴西和阿根廷,對可待因的取得寬鬆且監管嚴格,以適應不同的醫療保健能力和經濟狀況。在歐洲,可待因被廣泛用於監管良好的疼痛管理通訊協定中,特別是在西歐。在中東,對含有可待因和其他藥物的疼痛管理解決方案的需求不斷成長。然而,中東地區的監管機構對提供處方可待因實施了嚴格的規定,以避免濫用可待因。在非洲,正在製定法律規範以促進鴉片類藥物(包括可待因)的醫療應用,從而促進市場成長。在亞太地區,中國、日本、印度和澳洲等國家實施了嚴格的法規來遏制可待因的濫用,強調處方通訊協定和預防性公共衛生宣傳活動。此外,擴大醫療基礎設施和提高對慢性疼痛的認知正在推動該地區的市場成長。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在可待因市場中的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對可待因市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並制定有效的策略來提高其市場競爭力。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對可待因市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[185 Pages Report] The Codeine Market size was estimated at USD 3.93 billion in 2023 and expected to reach USD 4.11 billion in 2024, at a CAGR 4.65% to reach USD 5.40 billion by 2030.
Codeine, an opioid and prodrug of morphine, is utilized for its analgesic, antitussive, and antidiarrheal effects. It is formulated into various medications, such as tablets and syrups, or combined with other medicines. Increasing the prevalence of chronic diseases with often chronic pain is elevating the need for effective analgesics identical to codeine. An increasing geriatric population and continuous expansion of the healthcare infrastructure, particularly in developing economies, drive market growth. However, the market expansion is hindered by stringent regulations owing to codeine's potential for abuse and the ongoing global opioid crisis, which has led to a decline in opioid prescriptions, including those for codeine. Rising research & development activities for developing abuse-deterrent formulations that maintain therapeutic efficacy are expected to create opportunities for market growth. The rising exploration of novel drug delivery systems, including extended-release capsules and precision medicine approaches tailored to individuals' genetic profiles, is expanding the market scope.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.93 billion |
Estimated Year [2024] | USD 4.11 billion |
Forecast Year [2030] | USD 5.40 billion |
CAGR (%) | 4.65% |
Regional Insights
In the Americas, the United States and Canada have robust pharmaceutical industries that facilitate the production and distribution of codeine medication. Moreover, ongoing research and development efforts for innovations in pain management therapies, including codeine, are expected to create a platform for market growth in the Americas. While in South American countries, specifically Brazil and Argentina, feature moderate accessibility to codeine under vigilant regulations, addressing varying healthcare capacities and economic conditions. In Europe, codeine is widely used within well-regulated pain management protocols, particularly in Western Europe. In the Middle East, there is an increase in the need for pain management solutions, including codeine with other medications. However, the regulatory authorities in the region enforce strict regulations to provide the prescribed codeine medication to avoid misuse of codeine in the Middle East region. In Africa, ongoing development in regulatory framework has boosted the healthcare application of an opioid class of medication, including codeine, contributing to market growth. In Asia Pacific, countries such as China, Japan, India, and Australia enforce stringent regulations to curb codeine misuse, emphasizing prescription protocols and preventive public health campaigns. Moreover, expanding healthcare infrastructure and improving awareness about chronic pain conditions drive market growth in the region.
Market Insights
The market dynamics represent an ever-changing landscape of the Codeine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Codeine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Codeine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Advancements in Developing Enhanced Pain Relief Medications
Researchers at UNC Health have made significant strides in perfecting pain relief medications, focusing expressly on minimizing side effects associated with opioid use. This latest study emphasized designing drugs that provide effective pain management while substantially reducing the potential for addiction and other serious side effects such as respiratory depression. The scientists employed advanced molecular technology to understand better opioid receptors' behavior, which has led to the creation of molecules that target pain pathways more precisely. This breakthrough could revolutionize how pain is managed, offering relief to patients with chronic and acute pain conditions and potentially curtailing the opioid crisis by providing safer alternatives. [Published On: 2023-01-12]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Codeine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Codeine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accord Healthcare by Intas Pharmaceuticals, Advik Pharma, AstraEureka Pharmaceuticals, Bristol Laboratories Limited, Crescent Pharma Limited, Johnson Matthey Plc, Noramco, Inc., Omnica Laboratories, Pfizer Inc., Professional Compounding Centers of America, Inc., SANOFI WINTHROP INDUSTRIE, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage